Therese Liechtenstein, PhD, is a Principal in the Biotechnology team of M Ventures. Therese joined M Ventures in 2018. She was instrumental in the creation and financing of multiple companies of M Ventures portfolio, including FoRx Therapeutics and Anavo Therapeutics. Thera actively leads investments and represents M Ventures on the board of multiple portfolio companies. Previously Therese managed strategic projects for the Healthcare business of Merck KGaA in Darmstadt, Germany. Prior to Merck KGaA, Darmstadt, Germany, Therese was a client relationship manager in the field of wealth preservation, at Industrie- & Finanzkontor Ets. Therese comes from an academic background receiving her PhD in Immuno-Oncology from University College London, an MSc in Biomedical Sciences from the University of Amsterdam, and a BA in Biology and Business studies from New York University.